Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
FDA approves new B&L contact lens material
The FDA has cleared the use of the new Bausch & Lomb (B&L) Boston XO2 gas-permeable contact lens material for daily wear in patients with ametropia and certain irregular corneal conditions, the company announced.
Rochester, NY-The FDA has cleared the use of the new Bausch & Lomb (B&L) Boston XO2 gas-permeable contact lens material for daily wear in patients with ametropia and certain irregular corneal conditions, the company announced.
Lenses made with this new contact lens material allow 40% more oxygen to reach the eye than the original Boston XO material, said the eye-care company, which is being acquired by Warburg Pincus
Related Videos
Related Content
